Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis

Current Opinion in Hematology

Volumn 17, Issue 3, 2010, Pages 219-224

  Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Bv8; Granulocyte colony stimulating factor; Stroma; Tumor; Vascular endothelial growth factor

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; AFLIBERCEPT; ANGIOPOIETIN RECEPTOR; AXITINIB; BEVACIZUMAB; CD11B ANTIGEN; CYTOKINE; CYTOKINE ANTIBODY; ENZYME INHIBITOR; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR ANTIBODY; GROWTH FACTOR; GW 2580; IRINOTECAN; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PROTEIN BV8; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BONE MARROW CELL; BREAST CANCER; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MONOCYTE; NEUTROPHIL; NONHUMAN; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; HUMANS; MYELOID CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77951498489     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283386660     Document Type: Review

References (87)

1. Red-Horse K, Crawford Y, Shojaei F, Ferrara N. Endothelium-microenviron- ment interactions in the developing embryo and in the adult. Dev Cell 2007; 12:181-194.
2. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007; 58:491-504.
3. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974.
5. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2008; 335:261-269.
6. Ferrara N, Carver Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-442.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 9:669-676.
8. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-844.
9. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8:579-591.
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611. (Pubitemid 39099316)
11. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438:946-953.
12. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-660.
13. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N Engl J Med 2006; 355: 2542-2550.
17. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
18. Escudier B, PluzanskaA, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2008; 370:2103-2111.
19. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12:5018-5022.
20. Escudier B, EisenT, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
21. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008; 134:379.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
23. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-1295.
24. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116:642-651.
25. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
26. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to antiangiogenic therapies. Drug Resist Updat 2008; 11:219-230.
27. Shibuya M. Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis. BMB Rep 2008; 41:278-286.
28. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009; 30: 624-630.
29. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-314.
30. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
31. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239.
32. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08 [abstract LBA4]. J Clin Oncol 2009; 27:18s.
33. Shojaei F, Zhong C, Wu X, et al. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008; 18:372-378.
34. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
35. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
36. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117:1175-1183.
37. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-252.
38. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vascu-logenesis but not for angiogenesis: role of bone marrow-derived myelomo-nocytic cells. Cancer Cell 2008; 13:193-205.
39. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371:771-783.
40. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71-78.
41. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102.
42. Nolan DJ, Ciarrocchi A, MellickAS, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007; 21:1546-1558.
43. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-631.
44. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8:211-226.
45. De Palma M, Murdoch C, Venneri MA, et al. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28:519-524.
46. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178:7405-7411.
47. De Palma M, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 2009; 1796:5-10.
48. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-516.
49. Brown JL, Cao ZA, Pinzon-Ortiz M, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9:145-156.
50. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90:222-231.
51. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 2009; 16:183-194.
52. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008; 22:559-574.
53. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438:820-827.
54. Dawson MR, Duda DG, Fukumura D, Jain RK. VEGFR1-activity-independent metastasis formation. Nature 2009; 461:E4.
55. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13:5243-5248.
56. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162-179.
57. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174.
58. + myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35.
59. + myeloid cells. Nat Biotechnol 2007; 25:911-920.
60. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269:25646-25654.
61. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95:11709-11714.
62. Davis-Smyth T, Chen H, Park J, et al. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996; 15:4919-4927.
63. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-475.
64. BaisC, Wu X, YaoJ, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (in press).
65. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398.
66. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2009. [Epub ahead of print].
67. Mollay C, WechselbergerC, MignognaG, et al. Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur J Pharmacol 1999; 374:189-196.
68. LeCouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001; 412:877-884.
69. Li M, Bullock CM, Knauer DJ, et al. Identification of two prokineticin cDNAs: recombinant proteins potently contract gestrointestinal smooth muscle. Mol Pharmacol 2001; 59:692-698.
70. Shojaei F, WuX, Zhong C, et al. Bv8 regulates myeloid cell-dependent tumour angiogenesis. Nature 2007; 450:825-831.
71. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009; 106:6742-6747.
72. Zhong C, Qu X, Tan M, et al. Characterization and regulation of Bv8 in human blood cells. Clin Cancer Res 2009; 15:2675-2684.
73. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 2009; 115:3919-3923.
74. Perez FA, Fligner CL, Yu EY. Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. J Clin Oncol 2009; 27:e215-e217.
75. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-544.
76. +cells. PLoS One 2010; 5:e8611.
77. Patel S, Player MR. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem 2009; 9:599-610.
78. Stanley ER, Berg KL, Einstein DB, et al. Biology and action of colony-stimulating factor-1. Mol Reprod Dev 1997; 46:4-10.
79. Sherr CJ, Rettenmier CW, Sacca R, et al. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985; 41:665-676.
80. Aharinejad S, Paulus P, Sioud M, et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004; 64:5378-5384.
81. Paulus P, Stanley ER, Schafer R, et al. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006; 66:4349-4356.
82. Kubota Y, Takubo K, Shimizu T, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009; 206:1089-1102.
83. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-766.
84. Guo J, Marcotte PA, McCall JO, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006; 5:1007-1013.
85. SonpavdeG, Hutson TE, Rini BI.Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008; 17:741-748.
86. Conway JG, McDonald B, Parham J, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005; 102:16078-16083.
87. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15:21-34.